Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas : a phase II trial
Twenty-two previously untreated patients who had unresectable and metastatic pancreatic cancer were treated in a prospective phase II trial with high-dose continuous infusion epirubicin (45 mg/m2 once every 24 hours continuous infusion days 4 through 6) plus quinidine (495 mg once every 24 hours on days 1-6). There were no objective responses (0 of 18 evaluable patients). Subjective responses were achieved in 2 of 21 evaluable patients (9%), all of whom had good performance status (Eastern Cooperative Oncology Group: 0-1). Median survival was 5.7 months for the overall population. Two patients who exhibited symptomatic improvement achieved responses lasting 7 and 13 months, respectively. Toxicity was generally mild and tolerable. Little benefit regarding survival and quality of life was observed with the use of this regimen. The role in chemoresistance of mdrl, p53, and the mismatch repair system was examined.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1998 |
|---|---|
| Erschienen: |
1998 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
American journal of clinical oncology - 21(1998), 2 vom: 15. Apr., Seite 151-4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abad, A [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 14.04.1998 Date Revised 05.09.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM094785961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM094785961 | ||
| 003 | DE-627 | ||
| 005 | 20231222100419.0 | ||
| 007 | tu | ||
| 008 | 231222s1998 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0316.xml |
| 035 | |a (DE-627)NLM094785961 | ||
| 035 | |a (NLM)9537202 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abad, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas |b a phase II trial |
| 264 | 1 | |c 1998 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.1998 | ||
| 500 | |a Date Revised 05.09.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Twenty-two previously untreated patients who had unresectable and metastatic pancreatic cancer were treated in a prospective phase II trial with high-dose continuous infusion epirubicin (45 mg/m2 once every 24 hours continuous infusion days 4 through 6) plus quinidine (495 mg once every 24 hours on days 1-6). There were no objective responses (0 of 18 evaluable patients). Subjective responses were achieved in 2 of 21 evaluable patients (9%), all of whom had good performance status (Eastern Cooperative Oncology Group: 0-1). Median survival was 5.7 months for the overall population. Two patients who exhibited symptomatic improvement achieved responses lasting 7 and 13 months, respectively. Toxicity was generally mild and tolerable. Little benefit regarding survival and quality of life was observed with the use of this regimen. The role in chemoresistance of mdrl, p53, and the mismatch repair system was examined | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a ATP Binding Cassette Transporter, Subfamily B, Member 1 |2 NLM | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a Epirubicin |2 NLM | |
| 650 | 7 | |a 3Z8479ZZ5X |2 NLM | |
| 650 | 7 | |a Quinidine |2 NLM | |
| 650 | 7 | |a ITX08688JL |2 NLM | |
| 700 | 1 | |a Massuti, B |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, E |e verfasserin |4 aut | |
| 700 | 1 | |a Carrato, A |e verfasserin |4 aut | |
| 700 | 1 | |a Maurel, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cervantes, A |e verfasserin |4 aut | |
| 700 | 1 | |a Aranda, E |e verfasserin |4 aut | |
| 700 | 1 | |a Antón, A |e verfasserin |4 aut | |
| 700 | 1 | |a Vicent, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Dorta, J |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia de Paredes, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Ariza, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of clinical oncology |d 1988 |g 21(1998), 2 vom: 15. Apr., Seite 151-4 |w (DE-627)NLM012605603 |x 1537-453X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:1998 |g number:2 |g day:15 |g month:04 |g pages:151-4 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 1998 |e 2 |b 15 |c 04 |h 151-4 | ||